Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Hangzhou Tigermed Consulting Co., Ltd. Class H ( (HK:3347) ) just unveiled an update.
Hangzhou Tigermed Consulting Co., Ltd. has convened a 2026 second H share class meeting in Hong Kong for holders of its H shares, to be held on June 9, 2026 after its extraordinary general and A share class meetings. The session will be conducted by poll, with a specified register closure period and proxy procedures outlined for shareholders wishing to participate.
At the meeting, shareholders will vote on a special resolution authorizing the repurchase of A shares through centralized price bidding, including terms covering purpose, scale, pricing and funding of the buyback. The proposed mandate, if approved, would give the board authority to execute the A share repurchase, potentially affecting the company’s capital structure and offering H share investors a say in how Tigermed manages its equity base.
The most recent analyst rating on (HK:3347) stock is a Buy with a HK$55.00 price target. To see the full list of analyst forecasts on Hangzhou Tigermed Consulting Co., Ltd. Class H stock, see the HK:3347 Stock Forecast page.
More about Hangzhou Tigermed Consulting Co., Ltd. Class H
Hangzhou Tigermed Consulting Co., Ltd. is a China-based contract research and development service provider in the pharmaceutical and life sciences industry, with its H shares listed in Hong Kong. The company focuses on offering clinical research, consulting and related services to support drug development for domestic and international clients.
Average Trading Volume: 1,802,608
Technical Sentiment Signal: Sell
Current Market Cap: HK$40.7B
For an in-depth examination of 3347 stock, go to TipRanks’ Overview page.